ArticleCanadian journal of public health = Revue canadienne de sante publique2026
Differences in higher-risk cannabis use outcomes across Canadian provinces and territories: A cross-sectional study.
Article in Canadian journal of public health = Revue canadienne de sante publique, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesIn 2018, Canada legalized and regulated the production and sale of cannabis for non-medical purposes. This paper examined the prevalence of 'higher risk' cannabis use outcomes across Canadian provinces and territories (PTs), with rates hypothesized to be lower in Quebec and higher in the territories.
methodsPast 12-month cannabis consumers from the 2023 and 2024 cycles of the Canadian Cannabis Survey were included (n = 7238). A previous study identified 16 higher risk cannabis use outcomes. Logistic regression models tested differences in each outcome by PT (10 provinces; three territories combined) or region (Western Canada, Ontario, Quebec, Atlantic Canada, territories).
resultsNewfoundland and the territories had the highest rates of frequent cannabis use, and Alberta had the highest rate of inhalable cannabis extract use. Consumers in Quebec reported among the lowest rates of five 'higher risk' outcomes (including frequent cannabis use, past 12-month use of inhalable cannabis extracts, and use of extracts containing > 30% THC). In contrast, they reported among the highest rates of several other outcomes, including consuming edibles/beverages with > 10 mg THC/unit (despite a provincial limit of 5 mg/unit) and obtaining cannabis from illicit sources. The territories had high rates of frequent cannabis use; however, they did not differ significantly from the provinces on most outcomes.
conclusionsQuebec continues to differ from other PTs in several domains. Differences are likely due to historically lower rates of cannabis use in Quebec, including lower use of extracts, combined with the province's restrictions on product sales, including cannabis products with > 30% THC.
Indexed as
Identifiers
42032371What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.